Monoclonal Antibody to CD166 and Method for Production Thereof
AssigneesJapan Science and Technology Agency, Osaka Prefecture University Public Corporation
InventorYasuhiro Tsukamoto
Life of this patent
Estimating the term…
Loading patent…
AssigneesJapan Science and Technology Agency, Osaka Prefecture University Public Corporation
InventorYasuhiro Tsukamoto
Estimating the term…
CD166 is a cell adhesion molecule belonging to an immunoglobulin superfamily that is expressed in an excessive amount on the tumor surface. If an monoclonal antibody specifically binding to the CD166 is obtained, it becomes possible to suppress growth of tumor cells, detect the cells, and supply a therapeutic drug thereto specifically. However, because the CD166 proteins are very similar to each other among mammals, it was not possible to obtain an antibody to human CD166, by immunizing, for example, mice with the human CD166. The antibody was prepared by immunizing mice with a purified avian CD166 protein. The antibody was found to be adsorbed on human and mouse CD166 proteins in vitro as well as in vivo and to have an action to suppress tumor growth in mice.
A monoclonal antibody, characterized by binding to a cell adhesion molecule CD166/ALCAM specifically.
A method of producing a monoclonal antibody, characterized by purifying the antibodies obtained from mice immunized with a CD166 protein of Phasianidae animal into a monoclonal antibody.
A cancer diagnosis method, characterized by monitoring progress of cancer, based on the CD166 content in blood.
Dependencies are inferred from the claim text.